In the last trading session, 1.23 million Amneal Pharmaceuticals Inc. (NYSE:AMRX) shares changed hands as the company’s beta touched 1.31. With the company’s per share price at $4.11 changed hands at $0.05 or 1.23% during last session, the market valuation stood at $1.24B. AMRX’s last price was a discount, traded about -15.33% off its 52-week high of $4.74. The share price had its 52-week low at $1.24, which suggests the last value was 69.83% up since then. When we look at Amneal Pharmaceuticals Inc.’s average trading volume, we note the 10-day average is 1.1 million shares, with the 3-month average coming to 1.16 million.
Analysts gave the Amneal Pharmaceuticals Inc. (AMRX) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 2.20. If we narrow down to specifics, the data shows that 1 out of 5 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended AMRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Amneal Pharmaceuticals Inc.’s EPS for the current quarter is expected to be $0.11.
Amneal Pharmaceuticals Inc. (NYSE:AMRX) trade information
Instantly AMRX was in green as seen at the end of in last trading. With action 9.02%, the performance over the past five days has been green. The jump to weekly highs of 4.22 on Friday, 09/15/23 added 1.23% to the stock’s daily price. The company’s shares are showing year-to-date upside of 106.53%, with the 5-day performance at 9.02% in the green. However, in the 30-day time frame, Amneal Pharmaceuticals Inc. (NYSE:AMRX) is 12.30% up. Looking at the short shares, we see there were 3.62 million shares sold at short interest cover period of 3.09 days.
Amneal Pharmaceuticals Inc. (AMRX) estimates and forecasts
Data shows that the Amneal Pharmaceuticals Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 204.44% over the past 6 months, a -22.06% in annual growth rate that is considerably lower than the industry average of 9.70%. Moreover, analysts have looked to lower expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Amneal Pharmaceuticals Inc. will fall -21.40%, while the growth in revenue is estimated to hit -39.10% for the next quarter. Year-over-year growth is forecast to reach 7.30% up from the last financial year.
Consensus estimates given by 5 financial analysts project the company’s revenue in the current quarter to hit an average of $587.36 million. 5 analysts are of the opinion that Amneal Pharmaceuticals Inc.’s revenue for the quarter ending Dec 2023 will be $628.97 million. The company’s revenue for the corresponding quarters a year ago was $561.86 million and $609.76 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 4.50%. The estimates for the next quarter sales put growth at 3.20%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 33.30%. The 2023 estimates are for Amneal Pharmaceuticals Inc. earnings to decrease by -19.10%, but the outlook for the next 5-year period is at -1.90% per year.
Amneal Pharmaceuticals Inc. is expected to release its next quarterly earnings report between November 02 and November 06.
Amneal Pharmaceuticals Inc. (NYSE:AMRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 11.05% of Amneal Pharmaceuticals Inc. shares while 64.77% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 72.81%. There are 64.77% institutions holding the Amneal Pharmaceuticals Inc. stock share, with Fosun International Ltd the top institutional holder. As of Jun 29, 2023, the company held 13.96% of the shares, roughly 21.52 million AMRX shares worth $88.45 million.
Vanguard Group Inc holds the second largest percentage of outstanding shares, with 8.52% or 13.14 million shares worth $53.99 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 3.99 million shares estimated at $16.4 million under it, the former controlled 2.59% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.31% of the shares, roughly 3.56 million shares worth around $14.64 million.